Basic Information
Clone | Daclizumab Biosimilar |
---|
Molecular Weight | 150 kDa |
---|
Endotoxin | <1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay |
---|
Sterility | 0.2 μm filtration |
---|
Aggregation | <5% Determined by SECP |
---|
Purity | >95% Determined by SDS-PAGE |
---|
Product Information
Production | Purified from cell culture supernatant in an animal-free facility |
---|
Purification | Protein A or G purification |
---|
Storage | 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing) |
---|
Target Background
Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.Daclizumab binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.
Immunogen Information
Isotype | Human IgG1 kappa |
---|
Immunogen | Human IL2RA(CD25) |
---|
RecommendedIsotype Control(s) | In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody |
---|
Recommended Dilution Buffer | 1×PBS pH 7.0 |
---|
* For research use only. Not for therapeutic or diagnostic purposes.